Kybella

What is Kybella?

Submental fullness, or a “double chin” may be the result of genetics, age, or weight gain. Frequently, however, even with weight loss, it is difficult to eradicate a double chin. Kybella is a synthetic substance designed to diminish this stubborn submental fullness. The active ingredient in Kybella is a synthetic version of deoxycholic acid, a substance that occurs naturally in the body. Deoxycholic acid breaks down fat cells, permanently destroying them, and eliminating excess fat in the process.

Who is a candidate for Kybella?

You may want to consier Kybella if you have concerns about:

  • Submental fullness (“double chin”) that persists despite being at a healthy weight
  • Lack of definition of the chin and jaw line
  • You would like to avoid or delay having neck liposuction or a neck lift

How is Kybella Injected?

Kybella is injected in the office setting. Prior to injection, a topical anesthesia will be applied. Using a fine needle, multiple injections will be made under the chin. The process will take about 20-30 minutes to complete. Most patients require multiple treatments, spaced about 1 month apart. The maximum number of treatments that can be performed is six. Once treatment is complete, no additional injections are required – the fat loss is permanent and the results are long-lasting,

Risks

All procedures are associated with risks. Risks associated with Kybella include bruising, numbness, swelling and areas of firmness. On rare occasions, temporary paralysis resulting in an uneven smile can occur. It is important to talk with Dr. Rovelo about the risks of the procedure and how the risks can be minimized to provide the best possible outcome.

Recovery

Kybella is injected in the office setting and takes about 20-30 minutes to perform. Patients will return to normal activities immediately afterward. Swelling, bruising, and numbness may persist for 1-2 weeks. Effects are seen after several weeks – once the fat cells are destroyed and removed by the body, and once the swelling has resolved.